Biotech IV Monitor

MLYS — Mineralys Therapeutics Inc.

$2.2B market cap · 0 upcoming readouts tracked

Clinical trial readout dates for Mineralys Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced.

Market cap$2.2B
Cash & investments$625M~11 quarters at last loss rate
Recent 8-K filings2latest 2026-11-04

In progress, no date published

Phase 2 Lorundrostat
Chronic Kidney Disease
date not published
Ongoing

Cash position

Mineralys Therapeutics Inc. reported $625M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). Its net loss for that quarter was $57M; at that rate the cash would last about 11 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-04
8-K Material Agreement — partnership or licensing deal2026-10-29

Companies working on similar indications

Discussion

No messages yet. If you follow MLYS, you can start the conversation.
Track MLYS in real time
See live implied volatility for MLYS and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on MLYS
Contact — questions or corrections about MLYS: dukeupt@gmail.com